Form 8-K - Current report:
SEC Accession No. 0001628280-18-004264
Filing Date
2018-04-13
Accepted
2018-04-13 17:05:59
Documents
3
Period of Report
2018-04-13
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K - CUMBERLAND ONCOLOGY a8k-cumberlandoncology.htm 8-K 32402
2 EXHIBIT 99.1 - CUMBERLAND ONCOLOGY pressrelease-cumberlandonc.htm EX-99.1 32410
3 cumberlanda13.gif GRAPHIC 10657
  Complete submission text file 0001628280-18-004264.txt   80681
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 000000000
Type: 8-K | Act: 34 | File No.: 001-33637 | Film No.: 18754943
SIC: 2834 Pharmaceutical Preparations